Septerna, INC 10-Q quarterly reports

Septerna, Inc. reported its first-quarter 2026 financial results, highlighting progress in its clinical-stage drug development programs and a significant increase in revenue driven by its collaboration with Novo Nordisk.

Septerna reported a net income of $8.2 million for Q3 2025, primarily driven by a $195 million upfront payment from Novo Nordisk and a $12.5 million milestone from Vertex, while advancing new drug candidates SEP-479 and SEP-631.

Septerna, Inc. reports increased losses but secures a transformative collaboration with Novo Nordisk, significantly extending its cash runway and validating its drug discovery platform.

Septerna, Inc. announces its financial results for the first quarter of 2025 and highlights a new global collaboration with Novo Nordisk A/S.

Septerna Inc., a clinical-stage biotechnology company, reported a net loss of $20.5 million for the third quarter of 2024, with significant increases in research and development expenses.